ID.1
Item
newly diagnosed type i diabetic patients
boolean
C0011854 (UMLS CUI [1,1])
C1320655 (UMLS CUI [1,2])
ID.2
Item
type i diabetes treated with basal-bolus regimen including 3 or more injections of regular human insulin per day
boolean
C0011854 (UMLS CUI [1,1])
C0087111 (UMLS CUI [1,2])
ID.3
Item
bmi, 26-40 kg/m2
boolean
C1305855 (UMLS CUI [1])
ID.4
Item
hba1c, 7.5%-10%
boolean
C0019018 (UMLS CUI [1])
ID.5
Item
median 2hrs post -prandial more than or equal to 140 mg/dl (more than or equal to 7.8 mmol/l)
boolean
C0428554 (UMLS CUI [1])
ID.6
Item
fpg more than or equal to 120 mg/dl (more than or equal to 6.7 mmol/l)
boolean
C0428554 (UMLS CUI [1])
ID.7
Item
willingness to accept, and ability to inject insulin glargine therapy
boolean
C0557978 (UMLS CUI [1])
ID.8
Item
pregnancy : the use of lantus & apidra during pregnancy is not contraindicated. however, in the absence of supportive data, sanofi- aventis pharmaceuticals cannot specifically recommend the use of lantus in this patient population
boolean
C0032961 (UMLS CUI [1])
ID.9
Item
the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial
boolean